Important Announcements

Nondiscrimination Statement Update

Boston Medical Center Health System complies with applicable Federal civil rights laws and does not discriminate on the basis of age, race, color, national origin (including limited English proficiency and primary language), religion, culture, physical or mental disabilities, socioeconomic status, sex, sexual orientation and gender identity and/or expression. BMCHS provides free aids and services to people with disabilities and free language services to people whose primary language is not English.

To see our full nondiscrimination statement, click here.

Campus Construction Update

Starting September 14, we’re closing the Menino building lobby entrance. This, along with the ongoing Yawkey building entrance closure, will help us bring you an even better campus experience that matches the exceptional care you've come to expect. Please enter the Menino and Yawkey buildings through the Moakley building, and make sure to leave extra time to get to your appointment. Thank you for your patience. 

Click here to learn more about our campus redesign. 

Lung Cancer Screening Eligibility and Evidence

The BMC Lung Cancer Screening Program was created to identify and assess patients at risk for lung cancer, with the goal of early diagnosis and treatment. Patients who are interested in lung cancer screening should talk with their primary care provider, or contact the BMC Lung Nodule Clinic at 617.638-5864.

Evidence Supporting Lung Cancer Screening

The National Lung Screening Trial (NLST) found a 20 percent reduction in relative risk of lung cancer death in patients who were screened using low dose chest CT scans.  Reduced mortality from lung cancer in patients undergoing screening with chest CT scans was also found in the Nederlands-Leuvens Longkanker Screenings Onderzoek (NELSON) trial. The results of the NLST and NELSON trials were published in the New England Journal of Medicine.

Eligibility for Lung Cancer Screening

The US Preventative Task Force (USPTF - Grade B recommendation) endorsed lung cancer screening with low dose chest CT for the following patient population:

  • Ages 50-80 (Medicare covers ages 50-77)
  • No signs or symptoms of lung cancer (e.g., hemoptysis, weight loss)
  • A 20+ pack-year history of smoking
  • Current smoker, or quit smoking within the past 15 years

For more information about the CMS and USPTF decisions, as well as eligibility criteria, refer to the full decision statements: